{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:45:17Z","timestamp":1792683917976,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":33,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2026-2-2093"],"award-info":[{"award-number":["2026-2-2093"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270133"],"award-info":[{"award-number":["82270133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570178"],"award-info":[{"award-number":["82570178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106952","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:23:08Z","timestamp":1788970988000},"page":"106952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factor VIII administration during emicizumab prophylaxis: how much is enough?"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-209X","authenticated-orcid":false,"given":"Runhui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106952_bib1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106952_bib2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106952_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","article-title":"Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis","volume":"110","author":"Yada","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106952_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","article-title":"Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients","volume":"115","author":"Nakajima","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106952_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/jcm11030801","article-title":"Current choices and management of treatment in persons with severe hemophilia A without inhibitors: a mini-Delphi consensus","volume":"11","author":"Coppola","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.106952_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072565","article-title":"Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA study): a multicentre open-label non-randomised clinical trial","volume":"13","author":"Takeyama","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.rpth.2026.106952_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2026.106849","article-title":"Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, non-randomized clinical trial","author":"Takeyama","year":"2026","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106952_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","article-title":"A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X","volume":"112","author":"Ogiwara","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106952_bib9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jth.14746","article-title":"An anti-factor IXa\/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A","volume":"18","author":"Takeyama","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106952_bib10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106952_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/hae.14662","article-title":"Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab","volume":"29","author":"Ogiwara","year":"2023","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926036101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926036101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:23:44Z","timestamp":1792682624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926036101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926036101"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106952","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor VIII administration during emicizumab prophylaxis: how much is enough?","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106952"}}